RÉSUMÉ
A substantial number of hereditary colorectal cancer (CRC) and colonic polyposis cannot be explained by alteration in confirmed predisposition genes, such as mismatch repair (MMR) genes, APC and MUTYH. Recently, a certain number of potential predisposition genes have been suggested, involving each a small number of cases reported so far. Here, we describe the detection of rare variants in the NTLH1, AXIN2, RNF43, BUB1, and TP53 genes in nine unrelated patients who were suspected for inherited CRC and/or colonic polyposis. Seven of them were classified as pathogenic or likely pathogenic variants (PV/LPV). Clinical manifestations of carriers were largely consistent with reported cases with, nevertheless, distinct characteristics. PV/LPV in these uncommon gene can be responsible for up to 2.7% of inherited CRC or colonic polyposis syndromes. Our findings provide supporting evidence for the role of these genes in cancer predisposition, and contribute to the determination of related cancer spectrum and cancer risk for carriers, allowing for the establishment of appropriate screening strategy and genetic counseling in affected families.
Sujet(s)
Polypose adénomateuse colique , Prédisposition génétique à une maladie , Humains , Femelle , Mâle , Adulte d'âge moyen , Adulte , Polypose adénomateuse colique/génétique , Ubiquitin-protein ligases/génétique , Axine/génétique , Tumeurs colorectales/génétique , Protéine p53 suppresseur de tumeur/génétique , Sujet âgé , Protein-Serine-Threonine Kinases/génétique , Protéines de liaison à l'ADN/génétique , Deoxyribonuclease (pyrimidine dimer)RÉSUMÉ
APC is a tumor suppressor gene that exerts its effect through the regulation of the Wnt signaling pathway. Loss of function mutations of the gene are associated with familial adenomatous polyposis (FAP). Early diagnosis in FAP patients is essential to prevent the development of colorectal cancer. Extraintestinal manifestations often precede the formation of the polyposis; therefore, these manifestations may serve as a clinical indicator for the condition. The aim of this study was to assess genotype-phenotype associations between the location of APC mutations and various extraintestinal features, mainly focusing on osseous and dental anomalies. Analyses of our cases and the mutations available in the literature with these manifestations revealed that mutations in the N-terminal region (amino acids 1-~1000) of the protein are more frequently associated with only osseous anomalies, whereas dental manifestations are more prevalent in mutations in the middle region (amino acids 1000-~2100). In addition, supernumerary teeth were found to be the most common dental feature. Since dental abnormalities often precede intestinal polyposis, dentists have a crucial role in the early identification of patients at risk.
Sujet(s)
Protéine de la polypose adénomateuse colique , Polypose adénomateuse colique , Mutation germinale , Humains , Protéine de la polypose adénomateuse colique/génétique , Polypose adénomateuse colique/génétique , Malformations dentaires/génétique , Études d'associations génétiques , Dent surnuméraire/génétique , Prédisposition génétique à une maladie , Mâle , FemelleRÉSUMÉ
BACKGROUND: Wnt/ß-catenin signalling impairment accounts for 85% of colorectal cancers (CRCs), including sporadic and familial adenomatous polyposis (FAP) settings. An altered PI3K/mTOR pathway and gut microbiota also contribute to CRC carcinogenesis. We studied the interplay between the two pathways and the microbiota composition within each step of CRC carcinogenesis. METHODS: Proteins and target genes of both pathways were analysed by RT-qPCR and IHC in tissues from healthy faecal immunochemical test positive (FIT+, n = 17), FAP (n = 17) and CRC (n = 15) subjects. CRC-related mutations were analysed through NGS and Sanger. Oral, faecal and mucosal microbiota was profiled by 16 S rRNA-sequencing. RESULTS: We found simultaneous hyperactivation of Wnt/ß-catenin and PI3K/mTOR pathways in FAP-lesions compared to CRCs. Wnt/ß-catenin molecular markers positively correlated with Clostridium_sensu_stricto_1 and negatively with Bacteroides in FAP faecal microbiota. Alistipes, Lachnospiraceae, and Ruminococcaceae were enriched in FAP stools and adenomas, the latter also showing an overabundance of Lachnoclostridium, which positively correlated with cMYC. In impaired-mTOR-mutated CRC tissues, p-S6R correlated with Fusobacterium and Dialister, the latter also confirmed in the faecal-ecosystem. CONCLUSIONS: Our study reveals an interplay between Wnt/ß-catenin and PI3K/mTOR, whose derangement correlates with specific microbiota signatures in FAP and CRC patients, and identifies new potential biomarkers and targets to improve CRC prevention, early adenoma detection and treatment.
Sujet(s)
Carcinogenèse , Tumeurs colorectales , Phosphatidylinositol 3-kinases , Sérine-thréonine kinases TOR , Voie de signalisation Wnt , Humains , Tumeurs colorectales/microbiologie , Sérine-thréonine kinases TOR/métabolisme , Projets pilotes , Phosphatidylinositol 3-kinases/métabolisme , Mâle , Femelle , Polypose adénomateuse colique/microbiologie , Polypose adénomateuse colique/génétique , Adulte d'âge moyen , Protéine de la polypose adénomateuse colique/génétique , Protéine de la polypose adénomateuse colique/métabolisme , Fèces/microbiologie , Microbiome gastro-intestinal , Sujet âgé , Adulte , Mutation/génétique , MicrobioteRÉSUMÉ
Cribriform morular thyroid carcinoma (CMTC) has been included within the group of thyroid tumors of uncertain histogenesis in the recent World Health Organization classification of endocrine tumors. Most CMTCs occur in young euthyroid women with multiple (and bilateral) thyroid nodules in cases associated with familial adenomatous polyposis (FAP) or as single nodules in sporadic cases. CMTC generally behaves indolently, while aggressiveness and mortality are associated with highgrade CMTC. This tumor histologically displays a distinctive combination of growth patterns with morular structures. Strong diffuse nuclear and cytoplasmic immunostaining for ßcatenin is the hallmark of CMTC. Tumor cells are also positive for thyroid transcription factor1 and for estrogen and progesterone receptors, but negative for thyroglobulin and calcitonin. It is possible that the CMTC phenotype could result from blockage in the terminal/follicular differentiation of follicular cells (or their precursor cells) secondary to the permanent activation of the Wnt/ßcatenin pathway. In CMTC, the activation of the Wnt/ßcatenin pathway is the central pathogenetic event, which in FAPassociated cases results from germline mutations of the APC regulator of WNT signaling pathway (APC) gene, and in sporadic cases from somatic inactivating mutations in the APC, AXIN1 and CTNNB1 genes. Estrogens appear to play a tumorpromoting role by stimulating both the PI3K/AKT/mTOR and the RAS/RAF/MAPK signaling pathways. Additional somatic mutations (i.e. RET rearrangements, or KRAS, phosphatidylinositol4,5bisphosphate 3kinase catalytic subunit α, telomerase reverse transcriptase or tumor protein 53 mutations) may further potentiate the development and progression of CMTC. While hemithyroidectomy would be the treatment of choice for sporadic cases without highrisk data, total thyroidectomy would be indicated in FAPassociated cases. There is insufficient clinical data to propose therapies targeting the Wnt/ßcatenin pathway, but multikinase or selective inhibitors could be used in a manner analogous to that of conventional thyroid tumors. It is also unknown whether adjuvant antiestrogenic therapy could be useful in the subgroup of women undergoing surgery with highrisk CMTC, as well as when there is tumor recurrence and/or metastasis.
Sujet(s)
Tumeurs de la thyroïde , Humains , Tumeurs de la thyroïde/anatomopathologie , Tumeurs de la thyroïde/génétique , Femelle , Voie de signalisation Wnt , Polypose adénomateuse colique/génétique , Polypose adénomateuse colique/anatomopathologie , bêta-Caténine/génétique , bêta-Caténine/métabolismeRÉSUMÉ
RATIONALE: Adenomatous polyposis (AP) is a genetic disorder characterized by the occurrence of numerous adenomatous polyps in the colon and rectum and can be classified into classical AP and attenuated AP (AAP). AAP is diagnosed when the number of observed adenomas is between 10 and 99. The detection of AAP is significantly increasing mainly due to the improvement of the imaging technique and application of the screening program for colorectal cancer detection. Currently, the germline variations of the APC and MUTYH genes are reported as the main cause of classical AP. However, the underlying genetic basis of AAP is not well understood. In this study, we report 2 cases of AAP with MSH6 variations. PATIENT CONCERNS: Both patients visited the hospital after multiple polyps were detected during colonoscopies conducted as part of their health checkups. DIAGNOSES: The 2 patients were diagnosed with AAP through colonoscopic examination at our hospital. INTERVENTIONS: The 2 received genetic consultation; and, for follow-up purposes, both patients agreed to be tested for an underlying genetic condition through next generation sequencing. And germline MSH6 variations were detected in both AAP patients. OUTCOMES: There was no recurrence for both patients for 3 years follow-up. LESSONS: Minor portion of AAP can cause by genetic mutation in MSH6, and further research is needed.
Sujet(s)
Polypose adénomateuse colique , Protéines de liaison à l'ADN , Humains , Mâle , Polypose adénomateuse colique/génétique , Polypose adénomateuse colique/diagnostic , Adulte d'âge moyen , Femelle , Protéines de liaison à l'ADN/génétique , Adulte , Coloscopie , Mutation germinaleSujet(s)
Polypose adénomateuse colique , Tumeurs du côlon , Intussusception , Humains , Intussusception/étiologie , Intussusception/diagnostic , Intussusception/imagerie diagnostique , Tumeurs du côlon/complications , Tumeurs du côlon/diagnostic , Polypose adénomateuse colique/complications , Polypose adénomateuse colique/diagnostic , Coloscopie , Maladies du côlon/diagnostic , Maladies du côlon/étiologie , Maladies du côlon/microbiologie , Maladies du côlon/imagerie diagnostique , Mâle , Femelle , Adulte d'âge moyen , TomodensitométrieRÉSUMÉ
BACKGROUND: Patients with familial adenomatous polyposis (FAP) develop early colorectal adenomas and if left untreated, progression to cancer is an inevitable event. Prophylactic surgery does not prevent further development of cancer in the rectal remnant, rectal cuff in patients with ileal pouch anal anastomosis (IPAA) and even on the ileal mucosa of the pouch body. The aim of this review is to assess long-term rates of cancer and adenoma development in patients with FAP after prophylactic surgery and to summarise current recommendations for endoscopic management and surveillance of these patients. MATERIALS AND METHODS: A systematic literature search of studies from January 1946 through to June 2023 was conducted using the PRISMA checklist. The electronic database PubMed was searched. RESULTS: Fifty-four papers involving 5010 patients were reviewed. Cancer rate in the rectal remnant was 8.8-16.7% in the western population and 37% in the eastern population. The cumulative risk of cancer 30 years after surgery was 24%. Mortality due to cancer in the rectal remnant is 1.1-11.1% with a 5-year survival rate of 55%. The adenoma rate after primary IPAA was 9.4-85% with a cumulative risk of 85% 20 years after surgery and a cumulative risk of 12% for advanced adenomas 10 years after surgery. Cumulative risk for adenomas after ileorectal anastomosis (IRA) was 85% after 5 and 100% after 10 years. Adenomas developed more frequently after stapled (33.9-57%) compared to hand-sewn (0-33%) anastomosis. We identified reports of 45 cancers in patients after IPAA of which 30 were in the pouch body and 15 in the rectal cuff or at the anastomosis. CONCLUSIONS: There was a significant incidence of cancer and adenomas in the rectal remnant and ileal pouch of FAP patients during the long-term follow-up. Regular endoscopic surveillance is recommended, not only in IRA patients, but also in pouch patients after proctocolectomy.
Sujet(s)
Polypose adénomateuse colique , Colectomie , Proctocolectomie restauratrice , Humains , Polypose adénomateuse colique/chirurgie , Proctocolectomie restauratrice/méthodes , Proctocolectomie restauratrice/effets indésirables , Colectomie/méthodes , Colectomie/effets indésirables , Adénomes/chirurgie , Interventions chirurgicales prophylactiques/méthodes , Tumeurs colorectales/chirurgieRÉSUMÉ
BACKGROUND: Patients with familial adenomatous polyposis (FAP) have an increased risk of thyroid nodular disease. Previous studies demonstrated that screening thyroid ultrasound (US) will allow detection of nodules in 38% and thyroid cancer in 2.6% of patients. The aim of this study is to define the value of serial US evaluation at identifying disease progression in patients with FAP. METHODS: Retrospective review from 2008 to 2023 at a single referral center. All patients with FAP and screening thyroid US were included. Patient demographics, initial US characteristics, follow-up regarding the development of new nodules and cancer were assessed using a Kaplan-Meier analysis. RESULTS: A total of 556 patients underwent screening. Fifty percent were male. Median age at first screening was 38 year old. Eighty percent underwent longitudinal follow-up for a median length of 7 years. At initial screening, 169 patients (30%) had nodules. For patients with normal baseline US, 14% developed a nodule overtime. A total of 20 patients (3.6%) were diagnosed with thyroid cancer. The cumulative incidence of initial and subsequent cancer was 4% by 5 years and 6% by 10 years, while the cumulative incidence of thyroid nodules was 40% and 48%, respectively. CONCLUSIONS: Based on the Kaplan-Meier analysis, ongoing longitudinal screening is warranted for patients with FAP as they are prone to thyroid cancer and nodule development overtime even when presenting with a baseline normal US. Additionally, these data demonstrate a slow development of thyroid cancer from a normal US, thus it is reasonable to consider selectively extending the screening interval for this population.
Sujet(s)
Polypose adénomateuse colique , Évolution de la maladie , Tumeurs de la thyroïde , Nodule thyroïdien , Échographie , Humains , Polypose adénomateuse colique/épidémiologie , Polypose adénomateuse colique/diagnostic , Polypose adénomateuse colique/complications , Mâle , Femelle , Adulte , Études rétrospectives , Nodule thyroïdien/épidémiologie , Nodule thyroïdien/anatomopathologie , Nodule thyroïdien/diagnostic , Nodule thyroïdien/imagerie diagnostique , Adulte d'âge moyen , Tumeurs de la thyroïde/épidémiologie , Tumeurs de la thyroïde/diagnostic , Tumeurs de la thyroïde/anatomopathologie , Tumeurs de la thyroïde/imagerie diagnostique , Jeune adulte , Incidence , Études de suiviRÉSUMÉ
SCOPE: Yogurt consumption is related to a decreased risk of colorectal cancer (CRC), but whether such association is causal remains unclear. Patients with familial adenomatous polyposis (FAP) are at increased risk of CRC development. Here, the study investigates the efficacy of yogurt for intestinal polyposis chemoprevention in ApcMin/+ mice, a preclinical model for human FAP. METHODS AND RESULTS: A 10-week yogurt supplementation (15 g kg-1) in ApcMin/+ mice significantly reduces the intestinal polyp number (6.50 ± 0.97 versus 1.80 ± 0.49; p < 0.001) compared to controls. 16S rRNA gene-based microbiota analysis suggests that yogurt supplementation may greatly modulate the gut microbiome composition, especially in the relative abundance of Lactobacillus and Bifidobacterium. Importantly, the fecal concentration of d-lactate (d-Lac, 0.39 ± 0.04 µmol g-1 versus 8.14 ± 0.62 µmol g-1; p < 0.001) is boosted by yogurt, while oral administration with d-Lac (125 or 250 mg kg-1) reduces the polyp number by 71.43% or 77.14% (p < 0.001), respectively. The study also observes that d-Lac does not affect cell viability and anchorage-independence in CRC cells, but it greatly suppresses epidermal growth factor (EGF) or 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced cell transformation in preneoplastic cells. Mechanistically, it demonstrates that d-Lac may attenuate epithelial cell transformation by targeting PI3K/AKT/ß-catenin axis. CONCLUSION: Yogurt protects against intestinal polyposis in ApcMin/+ mice, and d-Lac may partially account for the chemopreventive effects above.
Sujet(s)
Tumeurs colorectales , Microbiome gastro-intestinal , Yaourt , Animaux , Tumeurs colorectales/prévention et contrôle , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Polypose adénomateuse colique/génétique , Polypose adénomateuse colique/prévention et contrôle , Humains , Souris de lignée C57BL , Souris , Mâle , Acide lactique , Carcinogenèse/effets des médicaments et des substances chimiques , Fèces/microbiologie , Fèces/composition chimique , Protéine de la polypose adénomateuse colique/génétiqueRÉSUMÉ
BACKGROUND: Familial adenomatous polyposis (FAP) is an inherited disorder. At present, an increasing number of medications are being employed to treat FAP; however, only a few have been assessed for their efficacy and safety. Therefore, this study aimed to conduct a network meta-analysis to compare the therapeutic outcomes and adverse drug reactions of all FAP-associated medications. METHODS: Six relevant databases were searched to identify pertinent randomized controlled trials (RCTs), and information on the dosage and frequency of various drugs was extracted. Additionally, data on changes in polyp counts and dimensions, as well as treatment-related adverse reactions for different medications were collected. The Bayesian method was employed to directly or indirectly compare the impact of different treatment regimens on changes in polyp numbers and diameters, and the safety of the drugs was investigated. RESULTS: CXB at 16 mg/kg/day significantly reduced polyp numbers. Celecoxib at 8 mg/kg/day and sulindac (150 mg twice daily) plus erlotinib (75 mg/day) were effective for tolerant FAP patients. Additionally, EPAFFA 2 g daily and sulindac (150 mg twice daily) plus erlotinib (75 mg/day) emerged as the most effective for reducing polyp size. CONCLUSION: The most effective treatment for reducing the number of colorectal polyps is celecoxib 16 mg/kg/day. On the other hand, a daily dosage of 2 g EPA-FFA demonstrates the best results in terms of decreasing colorectal polyp diameter.
Sujet(s)
Polypose adénomateuse colique , Humains , Polypose adénomateuse colique/traitement médicamenteux , Méta-analyse en réseau , Évolution de la maladie , Essais contrôlés randomisés comme sujetRÉSUMÉ
INTRODUCTION: APC-associated polyposis is a rare hereditary disorder characterized by the development of multiple adenomas in the digestive tract. Individuals with APC-associated polyposis need to be managed by specialized multidisciplinary teams in dedicated centers. AREAS COVERED: The study aimed to review the literature on Familial adenomatous polyposis (FAP) to provide an update on diagnostic and surgical management while focusing on strategies to minimize the risk of desmoid-type fibromatosis, cancer in anorectal remnant, and postoperative complications. FAP individuals require a comprehensive approach that includes diagnosis, surveillance, preventive surgery, and addressing specific extracolonic concerns such as duodenal and desmoid tumors. Management should be personalized considering all factors: genotype, phenotype, and personal needs. Total colectomy and ileo-rectal anastomosis have been shown to yield superior QoL results when compared to Restorative Procto colectomy and ileopouch-anal anastomosis with acceptable oncological risk of developing cancer in the rectal stump if patients rigorously adhere to lifelong endoscopic surveillance. Additionally, a low-inflammatory diet may prevent adenomas and cancer by modulating systemic and tissue inflammatory indices. EXPERT OPINION: FAP management requires a multidisciplinary and personalized approach. Integrating genetic advances, innovative surveillance techniques, and emerging therapeutic modalities will contribute to improving outcomes and quality of life for FAP individuals.
Sujet(s)
Polypose adénomateuse colique , Colectomie , Qualité de vie , Humains , Polypose adénomateuse colique/thérapie , Polypose adénomateuse colique/chirurgie , Complications postopératoires/prévention et contrôle , Complications postopératoires/étiologie , Équipe soignante , Médecine de précision , Phénotype , Génotype , Fibromatose agressive/thérapie , Fibromatose agressive/anatomopathologieRÉSUMÉ
BACKGROUND: Hereditary adenomatous polyposis syndromes, including familial adenomatous polyposis and other rare adenomatous polyposis syndromes, increase the lifetime risk of colorectal and other cancers. METHODS: A team of 38 experts convened to update the 2008 European recommendations for the clinical management of patients with adenomatous polyposis syndromes. Additionally, other rare monogenic adenomatous polyposis syndromes were reviewed and added. Eighty-nine clinically relevant questions were answered after a systematic review of the existing literature with grading of the evidence according to Grading of Recommendations, Assessment, Development, and Evaluation methodology. Two levels of consensus were identified: consensus threshold (≥67% of voting guideline committee members voting either 'Strongly agree' or 'Agree' during the Delphi rounds) and high threshold (consensus ≥ 80%). RESULTS: One hundred and forty statements reached a high level of consensus concerning the management of hereditary adenomatous polyposis syndromes. CONCLUSION: These updated guidelines provide current, comprehensive, and evidence-based practical recommendations for the management of surveillance and treatment of familial adenomatous polyposis patients, encompassing additionally MUTYH-associated polyposis, gastric adenocarcinoma and proximal polyposis of the stomach and other recently identified polyposis syndromes based on pathogenic variants in other genes than APC or MUTYH. Due to the rarity of these diseases, patients should be managed at specialized centres.
Sujet(s)
Adénocarcinome , Polypose adénomateuse colique , DNA Glycosylases , Tumeurs de l'estomac , Humains , Polypose adénomateuse colique/génétique , Polypose adénomateuse colique/thérapie , Polypose adénomateuse colique/diagnostic , Tumeurs de l'estomac/génétique , Tumeurs de l'estomac/thérapie , Tumeurs de l'estomac/diagnostic , Adénocarcinome/génétique , Adénocarcinome/thérapie , Adénocarcinome/diagnostic , DNA Glycosylases/génétique , Syndromes néoplasiques héréditaires/génétique , Syndromes néoplasiques héréditaires/thérapie , Syndromes néoplasiques héréditaires/diagnostic , Europe , Polypes adénomateux/génétique , Polypes adénomateux/thérapie , PolypesSujet(s)
Polypose adénomateuse colique , Tumeurs du pancréas , Humains , Tumeurs du pancréas/génétique , Tumeurs du pancréas/métabolisme , Tumeurs du pancréas/anatomopathologie , Polypose adénomateuse colique/génétique , Femelle , Mâle , Protéine de la polypose adénomateuse colique/génétique , Adulte , Adulte d'âge moyen , Carcinome papillaire/anatomopathologie , Carcinome papillaire/génétique , MutationSujet(s)
Adénocarcinome , Polypose adénomateuse colique , Poches coliques , Proctocolectomie restauratrice , Humains , Adénocarcinome/chirurgie , Adénocarcinome/étiologie , Polypose adénomateuse colique/chirurgie , Poches coliques/effets indésirables , Tumeurs de l'iléon/chirurgie , Tumeurs de l'iléon/étiologie , Proctocolectomie restauratrice/effets indésirablesRÉSUMÉ
A 35-year-old woman of Asian descent with epigastralgia was referred to our hospital. Esophagogastroduodenoscopy revealed gastric cancer in the upper body and carpeting fundic gland polyposis in the fornix and body. Computed tomography revealed no metastases. Total colonoscopy and capsule endoscopy revealed no polyposis, except in the stomach. The patient was diagnosed with advanced gastric cancer and underwent open total gastrectomy. We speculated that her gastric cancer was a hereditary tumor due to its early onset and accompanying fundic gland polyposis. Germline multi-gene panel testing identified a single-nucleotide variant, c.-191 T > G, in exon 1B of the adenomatous polyposis coli gene, which can cause gastric adenocarcinoma and proximal polyposis of the stomach. To our knowledge, this is the first manuscript to report the variant (c.-191 T > G) in promoter 1B of the adenomatous polyposis coli gene, which is related to a predisposition to gastric adenocarcinoma and proximal polyposis of the stomach.
Sujet(s)
Adénocarcinome , Mutation ponctuelle , Tumeurs de l'estomac , Humains , Femelle , Adulte , Tumeurs de l'estomac/génétique , Tumeurs de l'estomac/anatomopathologie , Tumeurs de l'estomac/chirurgie , Adénocarcinome/génétique , Adénocarcinome/anatomopathologie , Régions promotrices (génétique)/génétique , Protéine de la polypose adénomateuse colique/génétique , Gastrectomie , Polypose adénomateuse colique/génétique , Polypose adénomateuse colique/chirurgie , Polypes adénomateuxRÉSUMÉ
ABCC3 (also known as MRP3) is an ATP binding cassette transporter for bile acids, whose expression is downregulated in colorectal cancer through the Wnt/ß-catenin signaling pathway. However, it remained unclear how downregulation of ABCC3 expression contributes to colorectal carcinogenesis. We explored the role of ABCC3 in the progression of colorectal cancer-in particular, focusing on the regulation of bile acid export. Gene expression analysis of colorectal adenoma isolated from familial adenomatous polyposis patients revealed that genes related to bile acid secretion including ABCC3 were downregulated as early as at the stage of adenoma formation. Knockdown or overexpression of ABCC3 increased or decreased intracellular concentration of deoxycholic acid, a secondary bile acid, respectively, in colorectal cancer cells. Forced expression of ABCC3 suppressed deoxycholic acid-induced activation of MAPK signaling. Finally, we found that nonsteroidal anti-inflammatory drugs increased ABCC3 expression in colorectal cancer cells, suggesting that ABCC3 could be one of the targets for therapeutic intervention of familial adenomatous polyposis. Our data thus suggest that downregulation of ABCC3 expression contributes to colorectal carcinogenesis through the regulation of intracellular accumulation of bile acids and activity of MAPK signaling.
Sujet(s)
Tumeurs colorectales , Acide désoxycholique , Régulation de l'expression des gènes tumoraux , Système de signalisation des MAP kinases , Protéines associées à la multirésistance aux médicaments , Humains , Polypose adénomateuse colique/métabolisme , Polypose adénomateuse colique/génétique , Polypose adénomateuse colique/anatomopathologie , Lignée cellulaire tumorale , Tumeurs colorectales/métabolisme , Tumeurs colorectales/anatomopathologie , Tumeurs colorectales/génétique , Acide désoxycholique/pharmacologie , Acide désoxycholique/métabolisme , Régulation négative , Protéines associées à la multirésistance aux médicaments/métabolisme , Protéines associées à la multirésistance aux médicaments/génétiqueRÉSUMÉ
PURPOSE: Patients with germline pathogenic variants (PVs) in APC develop tens (attenuated familial adenomatous polyposis [AFAP]) to innumerable (classic FAP) adenomatous polyps in their colon and are at significantly increased lifetime risk of colorectal cancer. Up to 10% of FAP and up to 50% of patients with AFAP who have undergone DNA-only multigene panel testing (MGPT) do not have an identified PV in APC. We seek to demonstrate how the addition of RNA sequencing run concurrently with DNA can improve detection of germline PVs in individuals with a clinical presentation of AFAP/FAP. METHODS: We performed a retrospective query of individuals tested with paired DNA-RNA MGPT from 2021 to 2022 at a single laboratory and included those with a novel APC PV located in intronic regions infrequently covered by MGPT, a personal history of polyposis, and family medical history provided. All clinical data were deidentified in this institutional review board-exempt study. RESULTS: Three novel APC variants were identified in six families and were shown to cause aberrant splicing because of the creation of a deep intronic cryptic splice site that leads to an RNA transcript subject nonsense-mediated decay. Several carriers had previously undergone DNA-only genetic testing and had received a negative result. CONCLUSION: Here, we describe how paired DNA-RNA MGPT can be used to solve missing heritability in FAP families, which can have important implications in family planning and treatment decisions for patients and their families.
Sujet(s)
Polypose adénomateuse colique , Tumeurs colorectales , Humains , Études rétrospectives , Polypose adénomateuse colique/diagnostic , Polypose adénomateuse colique/génétique , Polypose adénomateuse colique/anatomopathologie , Dépistage génétique , Tumeurs colorectales/génétique , ADNRÉSUMÉ
Recently, biallelic MSH3 germline pathogenic/likely pathogenic variants have been recognized as a rare cause of adenomatous polyposis. We present a 49-year-old woman who was admitted to our high-risk colorectal cancer clinic after incidental detection of a biallelic MSH3 (likely) pathogenic variant when tested for the germline (likely) pathogenic variants in hereditary breast and ovarian cancer related genes. The focus of this case report is to describe the genotype and phenotype of our patient with MSH3-related adenomatous polyposis. More than half of the polyps (13/19) were located in the right colon. In addition, benign and malignant extraintestinal lesions may be common as our patient had simple liver and kidney cysts and two basal cell skin carcinomas.(AU)
Recientemente, las variantes patogénicas/probablemente patogénicas de la línea germinal bialélica de MSH3 han sido reconocidas como una causa rara de poliposis adenomatosa. Presentamos a una mujer de 49 años que ingresó en nuestra clínica de cáncer colorrectal de alto riesgo después de la detección incidental de una variante patógena probable de la línea germinal MSH3 bialélica cuando se analizó la línea germinal variantes patogénicas/probablemente patogénicas en genes hereditarios relacionados con el cáncer de mama y de ovario. El objetivo de este informe de caso es describir el genotipo y el fenotipo de nuestro paciente con poliposis adenomatosa relacionada con MSH3. Más de la mitad de los pólipos (13/19) se localizaron en el colon derecho. Además, las lesiones extraintestinales benignas y malignas pueden ser comunes, ya que nuestra paciente tenía quistes hepáticos y renales simples y dos carcinomas cutáneos de células basales.(AU)
Sujet(s)
Humains , Mâle , Adulte d'âge moyen , Polypose adénomateuse colique , Génotype , Phénotype , Patients hospitalisés , Examen physique , Gastroentérologie , Maladies gastro-intestinalesRÉSUMÉ
OBJECTIVE: Aim: To explore the prevalence, clinical characteristics, and diagnostic aspects of diffuse familial adenomatous polyposis in childhood. This objective is accomplished through an extensive review of recent literature, and the presentation of case report from our clinical practice. PATIENTS AND METHODS: Materials and Methods: We analyzed 75 scientific papers, the findings of which have been documented in the PubMed database. Our search criteria included keywords such as âªdiffuse familial adenomatous intestinal polyposis,â« âªchildren,â« and âªdiagnosis.â« Then we conducted a second-stage analysis that involved a detailed review of a practical case - the medical records of inpatient Kh.V. who had been diagnosed with familial adenomatous polyposis. CONCLUSION: Conclusions: The analysis of the literature data is consistent with the findings from our clinical observations of familial adenomatous polyposis in a patient with complicated family anamnesis. It is worth noting that clinical features do not significantly differ across various types of polyposis. In cases of suspected familial adenomatous polyposis in adolescents, genetic testing is crucial.
Sujet(s)
Polypose adénomateuse colique , Adolescent , Humains , Polypose adénomateuse colique/diagnostic , Polypose adénomateuse colique/complications , Polypose adénomateuse colique/génétique , Intestins , Dépistage génétiqueRÉSUMÉ
In the Danish Polyposis Register, patients with over 100 cumulative colorectal adenomas of unknown genetic etiology, named in this study colorectal polyposis (CP), is registered and treated as familial adenomatous polyposis (FAP). In this study, we performed genetic analyses, including whole genome sequencing (WGS), of all Danish patients registered with CP and estimated the detection rate of pathogenic variants (PV). We identified 231 families in the Polyposis Register, 31 of which had CP. A polyposis-associated gene panel was performed and, if negative, patients were offered WGS and screening for mosaicism in blood and/or adenomas. Next-generation sequencing (NGS) was carried out for 27 of the families (four declined). PVs were detected in 11 families, and WGS revealed three additional structural variants in APC. Mosaicism of a PV in APC was detected in two families. As the variant detection rate of eligible families was 60%, 93% of families in the register now have a known genetic etiology.